Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
1997 1
2001 1
2004 2
2006 1
2007 2
2008 3
2009 8
2010 6
2011 4
2012 4
2013 10
2014 11
2015 15
2016 17
2017 10
2018 7
2019 6
2020 4
2021 3
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 28668839

104 results

Results by year

Filters applied: . Clear all
Page 1
A phase 2 study of bevacizumab in combination with carboplatin and paclitaxel in patients with non-squamous non-small-cell lung cancer harboring mutations of epidermal growth factor receptor (EGFR) after failing first-line EGFR-tyrosine kinase inhibitors (HANSHIN Oncology Group 0109).
Hattori Y, Satouchi M, Shimada T, Urata Y, Yoneda T, Mori M, Nishimura T, Sunadome H, Kumagai T, Imamura F, Fujita S, Kaji R, Hata A, Tachihara M, Morita S, Negoro S. Hattori Y, et al. Lung Cancer. 2015 Feb;87(2):136-40. doi: 10.1016/j.lungcan.2014.12.007. Epub 2014 Dec 19. Lung Cancer. 2015. PMID: 25553650 Clinical Trial.
Vascular Endothelial Growth Factor in Plasma and Pleural Effusion Is a Biomarker for Outcome After Bevacizumab plus Carboplatin-Paclitaxel Treatment for Non-small Cell Lung Cancer with Malignant Pleural Effusion.
Tamiya M, Tamiya A, Yasue T, Nakao K, Omachi N, Shiroyama T, Tani E, Hamaguchi M, Morishita N, Suzuki H, Okamoto N, Okishio K, Kawaguchi T, Atagi S, Hirashima T. Tamiya M, et al. Anticancer Res. 2016 Jun;36(6):2939-44. Anticancer Res. 2016. PMID: 27272808
Maintenance therapy with pemetrexed and bevacizumab versus pemetrexed monotherapy after induction therapy with carboplatin, pemetrexed, and bevacizumab in patients with advanced non-squamous non small cell lung cancer.
Karayama M, Inui N, Fujisawa T, Enomoto N, Nakamura Y, Kuroishi S, Yokomura K, Koshimizu N, Sato M, Toyoshima M, Shirai T, Masuda M, Yamada T, Imokawa S, Suda T. Karayama M, et al. Eur J Cancer. 2016 May;58:30-7. doi: 10.1016/j.ejca.2016.01.013. Epub 2016 Feb 27. Eur J Cancer. 2016. PMID: 26922170 Clinical Trial.
Induction pemetrexed and cisplatin followed by maintenance pemetrexed versus carboplatin plus paclitaxel plus bevacizumab followed by maintenance bevacizumab: a quality of life-oriented randomized phase III study in patients with advanced non-squamous non-small-cell lung cancer (ERACLE).
Galetta D, Pisconti S, Cinieri S, Pappagallo GL, Gebbia V, Borsellino N, Maiello E, Rinaldi A, Montrone M, Rizzo P, Marzano N, Sasso N, Febbraro A, Colucci G. Galetta D, et al. Clin Lung Cancer. 2011 Nov;12(6):402-6. doi: 10.1016/j.cllc.2011.06.006. Epub 2011 Aug 10. Clin Lung Cancer. 2011. PMID: 21831718 Clinical Trial.
PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous non-small-cell lung cancer.
Zinner RG, Obasaju CK, Spigel DR, Weaver RW, Beck JT, Waterhouse DM, Modiano MR, Hrinczenko B, Nikolinakos PG, Liu J, Koustenis AG, Winfree KB, Melemed SA, Guba SC, Ortuzar WI, Desaiah D, Treat JA, Govindan R, Ross HJ. Zinner RG, et al. J Thorac Oncol. 2015 Jan;10(1):134-42. doi: 10.1097/JTO.0000000000000366. J Thorac Oncol. 2015. PMID: 25371077 Free PMC article. Clinical Trial.
104 results